DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. Abbott Laboratories AbbVie Abiomed Achillion Acorda Therapeutics, Inc AGA Medical Alcon Altarum Amerigroup Corp. Amgen, Amylin, Anadys Angel Medical Systems, Aptus Endosystems, Lectures for CME) for >$5K/1% page 1 of 9; 10/01/2012
ARCA Biopharma Ardea Biosciences, Astellas Pharma US AstraZeneca Atritech Baxter Bayer US (Bayer AG/Bayer in Japan subsidiaries) Bayer HealthCare (formerly Berlex Labs) Bellerophon Therapeutics BioCryst Biomarin Biomarker Factory Biscardia, Boehringer Ingelheim Boston Scientific Bristol Myers Squibb CardioDx, Lectures for CME) for >$5K/1% 2 of 9;10/01/2010
Cardiovascular Systems, Cardioxyl Cempra, Cerexa, Charles River Laboratories Cochrane Collaboration Critical Diagnostics CSL Limited Cubist Daiichi Sankyo Co. Limited Dr. Reddy s Laboratories LTD Drip Drop Durata Therapeutics Edwards Lifesciences Elesvier Eli Lilly & EOCI Pharmacomm Ltd. Evalve, Lectures for CME) for >$5K/1% 3 of 9;10/01/2010
Lectures for CME) for >$5K/1% Exelixis, F2G, Ltd. Ferring Genentech General Electric Healthcare Genzyme Gilead Sciences, Glaxo SmithKline (GSK) HeartFlow Helsinn Healthcare Hologic, Idera Pharmaceutical, INC Inimex International Stem Cell Iris Molecular Diagnostics Janssen Pharmaceutica Products 4 of 9;10/01/2010
Janssen and Development, LLC Johnson & Johnson Johnson & Johnson Pharmaceutical & Development KAI Kaiser Permanente Life Masters Supported Self Care, Lilly Luitpold, MAQUET Cardiovascular LLC (formerly Boston Scientific Cardiac & Vascular) Medafor, Medtronic Vascular, (formerly Medtronic AVE) Medtronic, Merck & Co. Merck Group Merck Laboratories Lectures for CME) for >$5K/1% 5 of 9;10/01/2010
Lectures for CME) for >$5K/1% Merck Sharp & Dohme I.A. Miracor Medical Systems Molecular Insight Murdock Mylan Laboratories, Novartis Pharmaceutical Ophthotech OrbusNeich Orexigen Therapeutics, Ortho-McNeil- Janssen, OSI Eyetech Otsuka America Pharmaceutical Oxygen Biotherapeutics PENTA Medical Perosphere, Pfizer 6 of 9;10/01/2010
Pharmacyclics Pharmos Portola Pharmaceutical Progenics Protalix Purdue Pharma Reata Regado Biosciences, Regeneron, Revalesio Corp Roche Diagnostic Corp. Roche Group Roche Molecular Systems, RTI Health Solutions Sage Therapeutics Sanofi-Aventis Santaris Pharma A/S Schering-Plough Lectures for CME) for >$5K/1% 7 of 9;10/01/2010
Lectures for CME) for >$5K/1% Scios, Seaside Therapeutics Somahlution, Svelte Medical Sytems, Tacere Therapeutics Takeda Pharmaceutical Co. Tethys Bioscience TEVA industries The Medicines Thoratec Versartis, Vertex, Volcano Westat 8 of 9;10/01/2010
Lectures for CME) for >$5K/1% Column Explanations: (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds. research grant company supports the expenses associated with projects in the DUHS that are under my direction. (3) I provide educational activities or deliver occasional lectures that generate revenue company. All revenues from these activities are paid to the. None of it is taken for personal income. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. (4) I receive personal income outside of my salary for consulting or other services (Including CME) company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. (5) I receive personal income outside of my salary for consulting or other non-cme services company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. personally receive royalties in excess of $5,000 per year company. (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > $5,000 or > 1%. 9 of 9;10/01/2010